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ORIGINAL ARTICLE
Mitochondrial DNA Deletions and
Neurodegeneration in Multiple Sclerosis
Graham R. Campbell, MRes,1 Iryna Ziabreva, PhD,1 Amy K. Reeve, PhD,1
Kim J. Krishnan, PhD,1 Richard Reynolds, PhD,2 Owen Howell, PhD,2
Hans Lassmann, MD,3 Doug M. Turnbull, MD, PhD,1 and Don J. Mahad, MD, PhD1
Objective: Cerebral atrophy is a correlate of clinical progression in multiple sclerosis (MS). Mitochondria are now
established to play a part in the pathogenesis of MS. Uniquely, mitochondria harbor their own mitochondrial DNA
(mtDNA), essential for maintaining a healthy central nervous system. We explored mitochondrial respiratory chain
activity and mtDNA deletions in single neurons from secondary progressive MS (SPMS) cases.
Methods: Ninety-eight snap-frozen brain blocks from 13 SPMS cases together with complex IV/complex II
histochemistry, immunohistochemistry, laser dissection microscopy, long-range and real-time PCR and
sequencing were used to identify and analyze respiratory-deficient neurons devoid of complex IV and with complex
II activity.
Results: The density of respiratory-deficient neurons in SPMS was strikingly in excess of aged controls. The majority
of respiratory-deficient neurons were located in layer VI and immediate subcortical white matter (WM) irrespective of
lesions. Multiple deletions of mtDNA were apparent throughout the gray matter (GM) in MS. The respiratory-
deficient neurons harbored high levels of clonally expanded mtDNA deletions at a single-cell level. Furthermore,
there were neurons lacking mtDNA-encoded catalytic subunits of complex IV. mtDNA deletions sufficiently explained
the biochemical defect in the majority of respiratory-deficient neurons.
Interpretation: These findings provide evidence that neurons in MS are respiratory-deficient due to mtDNA
deletions, which are extensive in GM and may be induced by inflammation. We propose induced multiple deletions
of mtDNA as an important contributor to neurodegeneration in MS.
ANN NEUROL 2011;69:481–492
In the majority of patients, multiple sclerosis (MS)begins with a relapsing-remitting course followed by a
gradual progression of irreversible neurological impair-
ment (secondary progressive MS [SPMS]).1 Although the
whole brain atrophies with advancing disease, reflecting
loss of both neurons and axons, radiological studies with
long-term follow-up show accelerated gray matter (GM)
atrophy correlating with clinical disability during the
progressive stage of MS.2,3 Thus understanding the
mechanisms of neurodegeneration is vital for identifying
ways to intervene the progression of MS.4,5
Mitochondrial defects are increasingly recognized
to play a role in the pathogenesis of MS.6–10 Energy in
the form of ATP is most efficiently produced by mito-
chondria, which also play a role in calcium handling,
production of reactive oxygen species (ROS), and apo-
ptosis.11 Uniquely mitochondria harbor their own DNA
(mitochondrial DNA [mtDNA]), the only non-nuclear
DNA in cells, which encodes 13 polypeptides featured
in 4 of the 5 respiratory chain complexes.12 The impor-
tance of mtDNA for maintaining a healthy central
nervous system (CNS) is highlighted by a number of
primary mtDNA disorders, where the entirely nuclear
DNA-encoded complex of mitochondrial respiratory
chain, complex II, is spared.13,14 The loss of complex
IV (cytochrome c oxidase [COX]), the catalytic subunits
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of which are encoded by mtDNA, with intact complex
II (respiratory deficiency) is considered a histochemical
hallmark of biochemical defects in primary mtDNA
disorders.15
Besides inherited defects, induced mtDNA muta-
tions (deletions and point mutations) within neurons are
well recognized in aging and neurodegenerative disor-
ders.16–18 mtDNA is particularly vulnerable to oxidative
damage due to its presence in a highly oxidative environ-
ment and lack of protective histones.19,20 Processes that
repair double-stranded breaks have been proposed as an
important mechanism for the formation of mtDNA dele-
tions, the predominant type of induced mtDNA muta-
tions in neurodegeneration.17,18,20–22 As a single cell con-
tains many copies of mtDNA, for a biochemical defect
to manifest, the ratio between deleted to wild-type or
healthy mtDNA (heteroplasmy) needs to exceed a certain
threshold.23 The increase in heteroplasmy level is
through a process of clonal expansion whereby 1 muta-
tion becomes dominant within the cell.12,18,21,24 Interest-
ingly, different mutations expand in different cells in
cases with multiple mtDNA deletions.24 Therefore, to
explore mtDNA it is essential to focus on single cells,
particularly when investigating pathogenicity of mtDNA
mutations.
In this study, we explored mitochondrial respira-
tory chain activity (complex IV and complex II) histo-
chemically and mtDNA within single neurons in cere-
bral cortex and immediate subcortical white matter
(WM) from SPMS cases. We propose that bouts of
acute inflammation and diffuse chronic inflammation in
MS damage mtDNA and, through repair processes and
clonal expansion, give rise to high heteroplasmy levels
of mtDNA deletions in single cells and respiratory-
deficient neurons.
Materials and Methods
Autopsy Tissue
A total of 98 blocks (approximately 2.5 cm3) from 13 SPMS
cases and 76 blocks from controls were used in this investiga-
tion. MS and control frozen blocks, stored at 80C, were
obtained from the MS Society Tissue Resource, London (Table
1). Control cases had no known neurological disorder or pathol-
ogy and the age range was between 60 and 88 years. Mean age
of MS cases (54.9 6 13.5 years) was significantly lower than
controls (73.8 6 8.8 years, p ¼ 0.001). The postmortem delay
in hours between MS cases (11.8 6 4.8 hours) and controls
(16.1 6 7.2 hours) was not significantly different (p ¼ 0.103).
Clinical details were obtained from case reports, made available
by MS Society Tissue Resource. The Newcastle and North
Tyneside Local Research Ethics Committee approved the study.
Immunohistochemistry
Cryostat sections (15lm thick) were allowed to air dry for 90
min. Sections were fixed in 4% paraformaldehyde at 4C and
briefly washed. Antigen retrieval was carried out by boiling
sections in 1mM EDTA pH 8 for 1 min; 3% H2O2 was
used to block endogenous peroxidases. Primary antibodies
were diluted to the optimized concentrations and applied for
90 min (Supplementary Table S1). Sections were developed
using either chromogens (DAB and VectorV
R
SG) or secondary
antibody directly conjugated to rhodamine (Jackson Immuno-
research), as previously described.8 Appropriate stainings were
carried out to exclude cross-reactivity and nonspecific binding
of antibodies.
TABLE: Clinical Details of All Cases Used in This
Investigation
Case Age at
death
(yr)
Diagnosis Disease
duration
(yr)
PM
interval
(hr)
MS1 39 SP 21 8
MS2 40 SP 12 10
MS3 42 SP 18 18
MS4 42 SP 6 15
MS5 46 SP 8 7
MS6 51 SP 10 6
MS7 53 SP 11 12
MS8 56 SP 26 11
MS9 57 SP 33 8
MS10 64 SP 36 11
MS11 71 SP 35 23
MS12 73 SP 52 10
MS13 80 SP 36 15
CON1 60 NA NA 5
CON2 64 NA NA 13
CON3 67 NA NA 17
CON4 69 NA NA 12
CON5 75 NA NA 22
CON6 76 NA NA 14
CON7 77 NA NA 18
CON8 78 NA NA 9
CON9 84 NA NA 30
CON10 88 NA NA 21
CON ¼ controls; MS ¼ multiple sclerosis; NA ¼ not
applicable; PM ¼ postmortem; SP ¼ secondary progressive
MS.
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Characterization of the GM lesions was based on previ-
ous work.25 Both human leukocyte antigen (HLA) and leuko-
cyte common antigen (LCA) antibodies were used to detect
inflammation in relation to lesions. Type I or leukocortical
lesions span GM and WM, type II lesions are intracortical, of-
ten surrounding a blood vessel, and type III or subpial cortical
lesions extend from the pial surface partially through the cortex
and sparing the deeper layers.25,26
Complex IV/Complex II Histochemistry
Mitochondrial respiratory chain activity was determined using
sequential complex IV(COX)/complex II (succinate dehydro-
genase [SDH]) histochemistry. Complex IV activity was
detected using COX medium.15 Sections were washed twice in
PBS and the SDH medium, an indicator of complex II activity,
was applied.15 Sections were dehydrated in 70%, 95%, and
100% ethanol and mounted in an aqueous medium. To iden-
tify neurons, NeuN was immunofluorescently labeled following
COX/SDH histochemistry. The sections were then prepared as
for immunohistochemistry.
Microscopy and Quantitation
A Zeiss Axioplan microscope was used to obtain brightfield and
fluorescent images. All high-magnification images were taken at
100 with an oil lens. To determine respiratory-deficient neu-
ron density, total GM, and immediate subcortical WM—identi-
fied as the WM region bordering and within 250lm from layer
VI—areas were calculated separately by scanning the entire sec-
tions at low magnification and measuring regions of interest
using the AxioVision 4.8 program. Neurons with a NeuN-
labeled nucleus were included in the quantitation. Respiratory-
deficient neurons were mapped in subcortical and cortical
regions twice by 2 investigators who were blinded to the distri-
bution of lesions and type of case.
For neuronal counts, GM and subcortical regions were
imaged at 10 magnification (Zeiss Axioplan) in both MS
cases and controls. Cells with NeuN-positive nuclei and with
NeuN staining in the cytoplasm, frequently observed, were then
recorded using Image ProV
R
. For an unbiased quantitation, NeuN-
positive cells at least 10lm in diameter and with a nucleus were
included by setting a threshold. Maps of cortical and WM lesions
were made and superimposed to determine the relation of respira-
tory deficiency to lesions. Quantitation was performed by an
individual blinded to case details and lesion location.
Inflammatory cell counts were based on the number of
HLA-positive cells in a 10 magnification field (4 fields
per region). Type I lesions were divided into WM and GM
components. The association of inflammatory cells to respiratory-
deficient cells was explored using brightfield combined with im-
munofluorescent histochemistry images using a Zeiss Axio-
Imager2 at 63.
Terminal Deoxynucleotidyl Transferase-
Mediated dUDP Nick-End Labeling
Terminal deoxynucleotidyl transferase-mediated dUDP nick-end
labeling (TUNEL; Roche) was carried out per manufacturer’s
guidelines following COX/SDH histochemistry. Cells were
identified at 100 magnification.
Laser Microdissection and DNA Extraction
For laser microdissection, cryostat sections (20lm thick) were
mounted onto membrane slides (Leica) and histochemistry was
performed. Tissue (approximately 250  250 lm2) was dis-
sected from normal-appearing GM (NAGM), normal-appearing
immediate subcortical WM and GM lesions (type I and type
III) separately in several serial sections using a Leica laser
microdissection microscope (Leica LMD). To determine
mtDNA deletions at a single-cell level, both respiratory-efficient
(intact complex IV activity) and respiratory-deficient (devoid of
complex IV and with complex II activity) neurons were micro-
dissected from GM and immediate subcortical WM. DNA
extraction was carried out using the QIAamp DNA Micro Kit
(Qiagen) per manufacturer’s guidelines.
Long-Range PCR
Long-range PCR, a well-established technique in diagnostic mi-
tochondrial laboratories, was used to detect mtDNA deletions
irrespective of the heteroplasmy level in MS cases and controls.
PCR reactions were performed using the Expand Long Tem-
plate PCR System (Roche) on extracted DNA from 250 
250-lm2 regions and pooled single neurons. To obtain a satis-
factory amount of DNA for long range, 5 or 2 neurons were
pooled at a time. The following conditions were used for the
PCR system: 3 min at 93C; 10 cycles of 93C for 30 sec,
58C for 30 sec, and 68C for 12 min; 20 cycles of 93C for
30 sec, 58C for 30 sec, and 68C for 12 min plus 5 sec per
additional cycle; and a final extension of 11 min at 68C. The
product was diluted 1:30 and 1ll used as a template for a sec-
ond round using the same conditions as above. Primers used
for the study covered the majority of the major arc (Supple-
mentary Fig S1). Long-range products were separated using a
0.7% agarose gel containing ethidium bromide and viewed
under UV light. Wild-type DNA from control blood was used
as a positive control.
Gel Extraction and Sequencing
To confirm mtDNA deletions in neurons, amplified products
were extracted using the Qiagen gel extraction kit per the man-
ufacturer’s instructions. The final concentration of DNA was
determined using a spectrophotometer (NanodropV
R
). A total of
2ll of ExoSAP was added to each sample while kept on ice.
Samples were then incubated for 15 min at 37C and 15 min
at 80. Cycle sequencing was set up on the samples using the
following master mix constituents: deionized water, 5
sequencing buffer, universal forward and reverse primers, and
Big Dye v3.1. The cycle sequencing program consisted of 1
min at 96C and 25 cycles of 10 sec at 96C, 5 sec at 50C,
and 4 min at 60C. Samples were sequenced on an ABI 3100
Genetic Analyzer (Applied Biosystems) and compared to the re-
vised Cambridge reference sequence (rCRS) with SeqScape soft-
ware (Applied Biosystems).
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Real-Time PCR
Real-time PCR, a technique designed to investigate hetero-
plasmy level rather than as a tool to rule out the presence of
mtDNA deletions, was used for the analysis of deletion levels
in COX-positive and COX-negative neurons. The multiplex
real-time MTND1/MTND4 assay was used to quantify levels of
mtDNA deletions in neurons.18,22,27,28 The assay provides a de-
letion (heteroplasmy) level in the neurons. A total of 5ll of
sample was used and run in triplicate in a 96-well plate. A 24-
ll master mix consisted of deionized water, TaqManV
R
Universal
mastermix (Applied Biosystems), 100nM ND1 VIC probe,
100nM ND4 FAM probe, 300nM ND1 FOR, 300nM ND1
REV, 300nM ND4 FOR, and 300nM ND4 REV primers
(Eurofins). The PCR program consisted of a 2-min incubation
at 50C, 10 min at 95C and 40 cycles of amplification; 15 sec
denaturation at 95C; and 1 min at 60C for hybridization of
probes and primers and DNA synthesis. Known deletion-level
standards, a blood-positive control and a blood-negative con-
trol, all run in triplicate, were added to the assays as previously
described.27
Statistics
SPSS version 17 was used for statistical analysis. Nonparametric
tests (Kruskal-Wallis test for differences between more than 2
groups and Wilcoxon-Mann-Whitney U-test for differences
between 2 groups) were used given the uneven distribution of
data. A p value of <0.05 was considered significant.
Results
Respiratory-Deficient Neurons Are Present in
Excess of Age in MS Cases
To identify respiratory-deficient neurons most likely to
harbor mtDNA deletions we used frozen tissue sections,
COX/SDH histochemistry, and immunofluorescent histo-
chemistry.12,18,28 The cells devoid of complex IV activity
and with complex II (respiratory-deficient) are stained
blue by the histochemical technique as opposed to the cells
with complex IV activity, which are stained brown (Fig
1A–C). Following COX/SDH histochemistry, respiratory-
deficient neurons were identified by immunofluorescent
labeling of NeuN (see Fig 1D, E). A comprehensive analy-
sis of 13 SPMS cases (see Table 1) with age ranging from
39 to 80 years showed a significantly greater density of
respiratory-deficient neurons (blue) in MS compared with
controls (age ranging from 60 to 88 years), despite MS
cases being significantly younger than controls (see Table
1). The majority of respiratory-deficient neurons were
located in cortical layer VI and immediate subcortical
WM of MS tissue. TUNEL-positive nuclei, caspase-9
expression, or nuclear translocation of apoptosis inducing
factor were not detected in respiratory-deficient neurons
(not shown). Moreover these neurons were not in close
contact with microglia (Supplementary Fig S2). Interest-
ingly, not all SPMS cases showed respiratory-deficient
neurons.
Respiratory-Deficient Neurons Are Globally
Distributed and Not Restricted to Lesions
Of the 98 snap-frozen blocks from the MS cases, 81 con-
tained 1 or more of the 3 types of cortical lesions, 96
lesions in total.25,26 Type I or leukocortical lesions
accounted for 39%(37/96), type II lesions accounted for
10%(11/96), and type III or subpial lesions accounted
for 50%(48/96) of the 96 cortical MS lesions. In terms
of WM lesions there were 17 in the 98 blocks, with 5
extending up to but sparing the cortex, as described by
Chang et al.29
We determined the prevalence of respiratory-
deficient neurons as a percentage of NeuN-positive cells
using adjacent sections, to account for neuronal loss.
Cortical layer VI and immediate subcortical WM were
considered because the majority of respiratory-deficient
neurons were located in these regions. Layer VI of leuko-
cortical (type I) lesions and WM lesions extending up to
the cortex were compared with the corresponding
normal-appearing white matter (NAWM) and NAGM in
MS cases and controls (Fig 2A–D). The density of
NeuN-positive cells was significantly lower in layer VI of
leukocortical (type I) lesions compared with NAGM in
MS and controls (see Fig 2C). A significant decrease in
neurons was also detected in the immediate subcortical
WM of MS lesions compared with corresponding
NAWM and regions in controls (see Fig 2D). When cor-
rected for neuronal loss, the percentage of respiratory-
deficient neurons in layer VI of type I lesions and
immediate subcortical WM of WM lesions extending up
to the cortex did not significantly differ when compared
with corresponding normal-appearing tissue regions.
Interestingly, there was a trend toward more respiratory-
deficient neurons in normal-appearing tissue compared
with lesions. We then compared the density of respiratory-
deficient neurons in MS based on location (frontal, parietal,
temporal, and occipital lobes). The difference in the percent
of respiratory-deficient neurons between the 4 locations was
not significant (see Fig 2E).
Mitochondrial DNA Deletions Are Widespread
in MS Cortex
We laser-microdissected regions (approximately 250
250lm2) from NAGM (all MS cases), cortical MS
lesions (4 MS cases), and GM from controls (4 cases) and
then extracted DNA for long-range PCR (Fig 3A–C) to
determine whether mtDNA deletions are present in MS
tissue. Multiple deletions of mtDNA were evident in 66%
of the 98 NAGM regions analyzed (see Fig 3D).
ANNALS of Neurology
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Deletions were also evident in 53% of the 32 lesions ana-
lyzed (51% in type I and 55% in type III). In compari-
son, only 16% of 37 analyzed regions from 4 aged con-
trols showed evidence of mtDNA deletions (see Fig 3E).
Interestingly, we did not find evidence of mtDNA dele-
tions by long-range PCR in 2 MS cases (MS02 and
MS07).
mtDNA Deletions Are Present Within Neurons
Given the likelihood that respiratory-deficient neurons
lacking complex IV and with complex II activity harbor
mtDNA deletions, we explored mtDNA extracted from
pooled laser-microdissected single neurons based on mor-
phology and NeuN labeling (Fig 4A). Long-range PCR
using DNA extracted from 5 pooled neurons with
FIGURE 1: Complex IV (COX)/complex II (SDH) histochemical detection of respiratory-deficient neurons in snap frozen MS
tissue sections. Complex IV (COX)/complex II (SDH) histochemistry on snap frozen sections from cases with secondary
progressive MS showed respiratory-deficient neurons (lacking complex IV and with complex II stained blue, arrowheads) as
well as neurons with intact complex IV activity (stained brown, arrow)(A, B) in the GM, (B) predominantly in layer VI, and (C)
immediate subcortical WM. Based on morphology both pyramidal and nonpyramidal neurons showed the mitochondrial
defect. The majority of respiratory-deficient neurons were located in layer VI (45%) and immediate subcortical white matter
(34%). (D, E) Respiratory-deficient cells in GM and WM were confirmed as neurons judged by NeuN immunofluorescent
labeling (inset shows respiratory-deficient neuron indicated by arrowhead). (F) The average density of complex IV–deficient
neurons, from a median of 7 blocks containing frontal, parietal, temporal, and occipital GM and immediate subcortical WM per
case, is shown in relation to age for MS cases (~) and controls (h). The average density represents respiratory-deficient
neurons in whole GM and immediate subcortical WM. The mean density of respiratory-deficient neurons in MS cases was
significantly greater (24.97 6 4.67 neurons/cm2, n 5 13) than aged control brains (1.59 6 0.86 neurons/cm2, n 5 10, p5
0.003). On average 18.54cm2 of GM and 2.26cm2 of immediate subcortical WM regions were examined per case. The mean
age of MS cases (54.9 6 13.5) was significantly lower than controls (73.8 6 8.8, p5 0.001). The postmortem delay between
MS cases (11.8 6 4.8 hours) and controls (16.1 6 7.2 hours) was not significantly different (p5 0.103). Differences between 2
groups were analyzed using the Wilcoxon-Mann-Whitney U-test. Error bars indicate standard error of the mean for each case;
6 values indicate standard deviation. COX 5 cytochrome c oxidase or complex IV; GM 5 gray matter; MS 5 multiple sclerosis;
SDH 5 succinate dehydrogenase or complex II; WM 5 white matter. [Color figure can be viewed in the online issue, which is
available at www.annalsofneurology.org.]
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FIGURE 2: Prevalence of respiratory-deficient neurons in relation to lesions in MS cases. Layer VI neurons in (A) leukocortical
(type I) lesions and (C) corresponding NAGM. (B, D) Immediate subcortical WM neurons within WM lesions extending up to the
cortex and corresponding NAWM areas [NAWM (SC)]. In A and B, respiratory-deficient neurons, as a percentage of all NeuN-
positive cells identified in serial sections, were not significantly different in lesion areas of layer VI (2.01 6 0.31 out of 1000
neurons in randomly selected type I lesions, n 5 22) and lesion areas of immediate subcortical WM (0.23 6 0.31 out of 1000
neurons, n 5 5) compared with corresponding NAGM (4.25 6 0.41 out of 1000 neurons, n 5 22) or WM (1.3 6 1.9 out of
1000 neurons, n 5 5) areas. There was a trend toward more respiratory-deficient neurons in normal-appearing tissue. In C and
D, neuronal loss in leukocortical (type I) lesions (in C, 461.49 neurons/mm2 6 97.91) and WM lesions extending up to the
cortical margin (in D, 75.76 neurons/mm2 6 36.15) was significant compared to corresponding normal-appearing tissue (GM:
541.93 neurons/mm2 6 91.19; WM: 109.64 neurons/mm2 6 34.84). Neuronal loss in lesion areas was also significant when
compared with corresponding areas in control cases (GM: 599.34 neurons/mm2 6 93.45; WM: 120.52 neurons/mm2 6 40.67).
The density of NeuN-positive cells in normal-appearing tissue was not significantly different compared with corresponding
regions in controls. In C and D, parentheses indicate the number of regions quantitated. (E) When the density of respiratory-
deficient neurons in GM and immediate subcortical WM in MS were determined with respect to location (frontal, parietal,
temporal, and occipital lobes, and plotted in order with frontal blocks to the left and occipital blocks to the right for each
case), the density of respiratory-deficient neurons did not significantly differ between the 4 lobes. Differences between 2
groups (in A and B) and more than 2 groups (in C–E) were analyzed using the Wilcoxon-Mann-Whitney U-test and Kruskal-
Wallis test, respectively. *p 5 0.005, **p 5 0.027, and **p 5 0.018 for GM and WM, respectively. Error bars and 6 indicate
standard deviation. GM 5 gray matter; NAGM 5 normal appearing gray matter; NAWM (SC)5 normal appearing white matter
(immediate subcortical region); MS 5 multiple sclerosis; WM 5 white matter.
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complex IV activity per lane identified multiple deletions
of mtDNA in these respiratory-efficient neurons (see Fig
4B). MtDNA deletions were also present in 5 pooled re-
spiratory-deficient neurons (see Fig 4C). In DNA pooled
from 2 respiratory-deficient neurons, the minimum num-
ber needed to extract a sufficient quantity of mtDNA for
long-range PCR, there were multiple deletions of
mtDNA (see Fig 4D). However, the number of mtDNA
deletions rarely exceeded the number of pooled neurons
in long-range PCR (see Fig 4C, D). Sequencing the
deleted mtDNA extracted from the long-range PCR
product verified the presence of mtDNA deletions and
characterized the breakpoints (see Fig 4E). All sequenced
mtDNA deletions confirmed removal of genes encoding
key subunits of respiratory chain complexes, except com-
plex II, which is entirely encoded by nuclear DNA, and
tRNAs (see Fig 4F). Nearly all deletions involved imper-
fect repeat sequences similar to previous findings within
neurons (Supplementary Table S2).30
mtDNA Deletions Are Expanded to High
Heteroplasmy Levels in Single
Respiratory-Deficient Neurons
In order to investigate the pathogenicity of mtDNA dele-
tions within neurons we determined the heteroplasmy level
of mtDNA deletions at a single-cell level in respiratory-
deficient neurons and compared with the levels in neu-
rons with intact complex IV activity (Fig 5A). The
FIGURE 3: mtDNA deletions are present throughout the GM in MS cases. A cortical MS lesion (arrowheads) is identified by (A)
lack of PLP and (B) presence of LCA staining. (C) Complex IV (COX)/complex II (SDH) histochemistry was performed in adjacent
sections mounted on membrane slides (Leica). In C, approximately 250 3 250-lm2 regions from lesions (*) and NAGM were
laser-microdissected. Scale bar: 250lm. Long-range PCR using DNA extracted from GM regions from (D) MS cases (shows
findings in MS03, aged 42 years) and (E) controls (shows findings in CON01 and CON09, aged 60 and 84 years, respectively)
show evidence of multiple deletions of mtDNA (amplified fragments smaller than 11kb). In D, MS cases, mtDNA deletions
were extensive in cortical lesions (lanes 1–4) and in NAGM (lanes 5–8). In E, aged controls, mtDNA deletions were less
apparent in cortical GM (all lanes) and only the wild-type bands (faint band at 11kb) were observed in a proportion of sampled
regions (lanes 2 and 4). In E, the mtDNA deletions in controls also vary in size consistent with multiple deletions of mtDNA as
evident in the lanes of cases CON1 and CON09. 1 indicates wild-type 11-kb band amplified from control DNA. Scale bar:
500lm. COX 5 cytochrome c oxidase or complex IV; GM 5 gray matter; LCA 5 leukocyte common antigen; NAGM 5 normal
appearing gray matter; MS 5 muscular sclerosis; PLP 5 proteolipid protein; SDH 5 succinate dehydrogenase or complex II;
WM 5 white matter. [Color figure can be viewed in the online issue, which is available at www.annalsofneurology.org.]
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mean heteroplasmy level of mtDNA deletions in single
respiratory-deficient neurons from 6 MS cases was signifi-
cantly greater than in neurons with intact complex IV ac-
tivity from MS cases and neurons from control cases (see
Fig 5A). Based on 95% confidence interval of hetero-
plasmy in respiratory-efficient neurons, 55% of respiratory-
deficient neurons in MS contained significantly higher hetero-
plasmy levels of mtDNA deletions. Neurons with high hetero-
plasmy levels of mtDNA deletions were found in young and
aged MS cases (see Fig 5B). We did not detect a significant dif-
ference in heteroplasmy levels between the WM and GM com-
ponents of type I lesions. The pathogenicity of mtDNA dele-
tions was further confirmed by the loss of catalytic subunits of
complex IV (COX-I and COX-II), which are encoded by
mtDNA, and genes for which are often absent in deleted
mtDNA (see Fig 5C, D).
Discussion
In this study we present evidence for the first time that
multiple deletions of mtDNA cause respiratory deficiency
within neurons as a result of clonal expansion in MS.
There were strikingly more neurons lacking complex IV
and with complex II activity (respiratory-deficient) in
SPMS cases compared with aged controls. The respiratory-
deficient neurons were distributed diffusely and found
irrespective of lesions. Our findings identify respiratory defi-
ciency due to mtDNA deletions as a potentially important
pathomechanism in MS.
Clonally expanded multiple deletions of mtDNA
causing respiratory deficiency are well recognized in neu-
rodegenerative disorders and aging.18,21,24,31 Despite the
FIGURE 4: mtDNA deletions are present within neurons in
MS. (A) Following complex IV (COX)/complex II (SDH)
histochemistry and immunofluorescent labeling of NeuN,
single respiratory-deficient neurons (i, arrowhead) and
neurons with complex IV activity (brown) were isolated from
membrane slides using laser microdissection (ii). Scale bar:
20 lm. (B) Long-range PCR identified multiple deletions of
mtDNA in respiratory efficient neurons (brown) when DNA
was extracted from 5 pooled, closely located neurons
(shown in each lane). mtDNA deletions were evident within
neurons throughout the MS GM (MS03 shown with each
lane representing different regions sampled from frontal,
parietal, temporal, and occipital lobes). When (C) 5 and (D)
2 respiratory-deficient neurons from MS cases were pooled
there was also evidence of mtDNA deletions. In D, the
minimum number of neurons needed to extract adequate
quantity of mtDNA for long-range PCR was 2. In C and D,
the number of mtDNA deletions detected by long-range
PCR rarely exceeded the number of respiratory-deficient
neurons pooled, consistent with clonal expansion. As
previously reported, the full-length product is not always
apparent, particularly when mtDNA deletions are present
possibly due to bias of PCR.28,31 (E, F) Sequencing of the
deleted mtDNA extracted from long-range PCR gels
identified the breakpoints of deletions, as shown in the
electropherogram, confirming both long-range and real-time
PCR findings. (G) The large-scale deletions encompassed much
of the major arc of the mitochondrial genome including genes
of complex I (green), complex III (red), complex IV (orange),
complex V (blue), and tRNAs (black). Scale bar: 10lm.
1 indicates wild-type 11kb band amplified from control DNA.
COX 5 cytochrome c oxidase or complex IV; GM 5 gray
matter; MS 5 muscular sclerosis; SDH 5 succinate dehydro-
genase or complex II. [Color figure can be viewed in the online
issue, which is available at www.annalsofneurology.org.]
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significantly younger age of MS cases the respiratory-
deficient neurons were more prevalent compared with
aged controls in this study. Given the vulnerability of
mtDNA to oxidative damage and the extent of inflamma-
tion in MS, often starting with a preclinical phase and
remaining throughout the disease course, mtDNA dele-
tions might be expected in MS.19,20 Repair of damaged
mtDNA rather than oxidative damage to mtDNA per se is
the most likely mechanism by which mtDNA deletions
are formed, and clonal expansion is regarded as the mech-
anism responsible for causing respiratory deficiency.20,21,24
Where respiratory deficiency is caused by induced multi-
ple DNA deletions, cells will have initially contained dele-
tions with different breakpoints, one of which then clo-
nally expands to high levels over time.23,24 Clonally
expanded multiple deletions of mtDNA are reported in
inclusion body myositis, a condition associated with
chronic inflammation.32,33 Our long-range and real-time
PCR findings within respiratory-deficient neurons from
SPMS cases are consistent with clonally expanded multiple
deletions of mtDNA. Study of mtDNA in other forms of
MS would be of interest. Our prediction in relapsing
remitting stage of MS (RRMS) is that inflammation
would still induce mtDNA deletions. However, mtDNA
deletions may not have had adequate time to expand to
threshold levels to cause respiratory deficiency in RRMS,
FIGURE 5: High heteroplasmy levels of mtDNA deletions in single respiratory-deficient neurons. (A) The heteroplasmy level of
mtDNA deletions at a single-cell level was determined using real-time PCR and DNA extracted from single neurons;
respiratory-deficient (blue) neurons contained significantly greater levels of mtDNA deletions (41.22%6 22.64), judged by ND1
and ND4 assay, compared with those with intact complex IV activity (brown) in MS cases (16.43%6 10.72, **p < 0.001) and
controls (20.31%6 13.71, *p5 0.001). Based on 95% confidence intervals of heteroplasmy level in respiratory-efficient neurons
(brown) from MS cases (n 5 6) and controls (n 5 5), 55% of respiratory-deficient neurons in MS cases had the increased
heteroplasmy levels. We did not find a correlation between heteroplasmy level and density of HLA-positive cells. Both GM and
WM neurons were analyzed (53% and 47%, respectively of all neurons analyzed). In total, 34, 56, and 80 single neurons were
included for control COX1, MS COX1, and MS COX2 neurons. (B) High heteroplasmy levels at a single neuronal level were
detected in respiratory-deficient neurons in MS cases, independent of age. Immunohistochemical labeling of (C) COX-I and (D)
COX-II in adjacent sections using DAB (brown), both of which are mtDNA-encoded catalytic subunits of complex IV, and NeuN
(VectorV
R
SG, blue) identify neurons lacking mtDNA-encoded subunits (arrowheads). Scale bar: 16 lm. Kruskal-Wallis test was
used to compare difference between groups. COX15 respiratory-efficient neurons with intact complex IV activity (brown
histochemical stain); COX25 respiratory-deficient neurons devoid of complex IV and with complex II activity; GM 5 gray
matter; HLA 5 human leukocyte antigen; MS 5 multiple sclerosis; WM 5 white matter. [Color figure can be viewed in the
online issue, which is available at www.annalsofneurology.org.]
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in which disease duration is shorter than in SPMS.
Whether mtDNA deletions and clonal expansion play a
role in the primary progressive form of MS needs
investigation.
We did not find an increase in density of respiratory-
deficient neurons in MS lesions where inflammation is most
prominent. In fact there was a trend toward a decrease in
respiratory-deficient neurons in lesions. Respiratory-deficient
neurons may be less capable of withstanding an inflamma-
tory environment. In lesions, neurons are exposed to a
number of insults and mitochondria may dysfunction as a
result of not only mtDNA deletions but also direct inhibi-
tion by nitric oxide, modification and inactivation of
subunits by peroxynitrite, and degradation of mRNA by
ROS.34–36 In environments with much less inflammation
than MS, clonally expanded mtDNA deletions cause neuro-
degeneration.37 Lack of TUNEL-positive nuclei, caspase
expression, and nuclear translocation of AIF in respiratory-
deficient neurons in MS and primary mitochondrial dis-
orders suggests the need for another local factor or ‘‘second
hit’’ before undergoing cell death.37 The slow rate of global
neuronal loss in chronic neurodegenerative disorders and
rapidity of apoptosis make the capture of apoptotic cells in
postmortem tissue difficult. In addition to the energy defect,
calcium handling is impaired in neurons harboring mtDNA
mutations.38 Neurons as well as axons and myelin with
mitochondrial defects are more susceptible to glutamate-
mediated injury, as illustrated in vitro using mitochondrial
respiratory chain inhibitors.8,39,40 Thus, decrease in density
of respiratory-deficient neurons in lesions is a likely reflection
of mtDNA deletion-mediated cell loss as well as increase in
susceptibility to other insults because of the clonally expanded
mtDNA deletions.
The presence of respiratory-deficient cells in fron-
tal, parietal, temporal, and occipital lobes irrespective of
lesions is supportive of the hypothesis that clonal expan-
sion of mtDNA is a random event.41,42 However, predi-
lection of layer VI for respiratory-deficient neurons har-
boring clonally expanded mtDNA deletions, despite
multiple deletions of mtDNA been present throughout
cerebral cortex albeit at low levels, suggests that WM
events may influence clonal expansion through soluble
factors. Layer VI involvement appears to be selective to
MS, as it has not been described with aging or in pri-
mary mitochondrial disorders, in which local factors,
yet to be identified, appear to trigger cell loss.37 Nitric
oxide is recognized to play a role in mitochondrial bio-
genesis and mtDNA replication.43 Faster rate of turn-
over of mtDNA and preferential replication of certain
mtDNA deletions may account for the above observa-
tion in MS.
The extent of mtDNA deletions identified using
long-range PCR on a global scale regardless of cell type,
and even in neurons with intact complex IV activity,
reflects the potential of cells in MS to become respiratory-
deficient through clonal expansion over the course of the
disease. By isolating individual neurons at a single time
point we identified high levels of multiple mtDNA dele-
tions within respiratory-deficient cells. In contrast,
mtDNA deletions detected by long-range PCR within
respiratory-efficient neurons in MS and controls were
not expanded to high levels. Blokhin et al.44 concluded
in a recent study that the pathology of MS was not
associated with an accumulation of complex IV–negative
cells and mitochondrial DNA deletions based on similar
findings to ours in respiratory competent cells but,
crucially, the authors did not study respiratory-deficient
neurons in MS cases. Furthermore, long-range PCR was
not used to detect mtDNA deletions in MS cases or
controls. Corresponding with our data, the authors did
report an increase in respiratory-deficient cells with age
in healthy individuals; however, MS cases over the age of
53 years were not included. There are several limitations
of the real-time PCR and single-cell analysis of mtDNA
deletions.27 Not all deletions may involve ND4 and
ND1, although rarely, may also be deleted. Isolation of
single neurons undoubtedly will result in inclusion of
some adjacent respiratory competent tissue, which would
dilute deleted mtDNA and hence reduce the hetero-
plasmy levels. Indeed, studies that report induced multiple
deletions of mtDNA show a wide spectrum for the hetero-
plasmy level in respiratory-deficient cells, similar to findings
in this study.18,27,33,45 The possibility that some of the
respiratory-deficient neurons may harbor clonally-expanded
mtDNA point mutations needs consideration.
Respiratory deficiency due to mtDNA deletions is
likely to be more extensive than that indicated by available
histochemical methods. The mtDNA deletions reported
in this study not only remove subunits of complex IV but
also complex I, complex V, and tRNAs, all of which will
significantly hamper ATP synthesis. Histochemical techni-
ques necessary to detect complex I, complex III, and com-
plex V activity at a single-cell level are not available. It is
becoming increasingly clear that the basis of energy deficit
in MS is multifactorial.6,8–10 With respect to neurons in
MS several transcripts of nuclear DNA–encoded subunits
of the mitochondrial respiratory chain as well as activity
of complex I and complex III were decreased in the
NAGM homogenates from frontal and parietal lobes in
patients with progressive disease.6,46 Oxidative damage to
mtDNA rather than mtDNA deletions were reported in
WM MS lesions.10 Once respiratory-deficient due to
clonally-expanded mtDNA deletions, the defect is likely
ANNALS of Neurology
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to be irreversible and unresponsive to immunomodulatory
therapy, unlike mitochondrial dysfunction due to modifi-
cation of transcripts or respiratory chain proteins. Our
findings suggest that inflammation-mediated damage to
mtDNA, mtDNA repair processes, and clonal expansion
of mtDNA mutations are potential therapeutic targets
particularly relevant to the progressive stage of SPMS.20
These findings identify mtDNA deletions, induced
by inflammation and clonally expanded at a single-cell
level causing respiratory deficiency, as potentially impor-
tant contributors to the pathogenesis of MS. We propose
the combination of increased neuronal vulnerability due
to mtDNA deletions and a ‘second hit’ from chronic
inflammation as an important basis of neurodegeneration
in the progressive stage of MS. Protection of mitochon-
dria and mtDNA in MS may help to reduce the irrevers-
ible decline of neurological function.
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